IL-6 as a marker for AML chemotherapy sensitivity
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at whether a protein called IL-6 can help predict how well chemotherapy will work in people with acute myeloid leukemia (AML) who haven't been treated before. It aims to find better ways to personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) for the first time.
- You have not received any chemotherapy for this AML yet.
- You join the study with a family member and sign a consent form.
- You do not have another cancer that needs treatment.
- You do not have an active infection like viral hepatitis or HIV/AIDS.
- You have not had major surgery in the last 3 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks a simple blood test called the D-index to see how well it predicts infections or other complications during standard chemotherapy for newly diagnosed acute myeloid leukemia (AML). It may help doctors better manage your care.
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.